NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

FibroGen Inc (MX: FGEN)

 
FGEN Technical Analysis
5
As on 14th Oct 2025 FGEN STOCK Price closed @ 199.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 19.91 & Strong Buy for SHORT-TERM with Stoploss of 15.26 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

FGENSTOCK Price

Open 199.00 Change Price %
High 199.00 1 Day -6.00 -2.93
Low 199.00 1 Week -24.00 -10.76
Close 199.00 1 Month 192.87 3146.33
Volume 21 1 Year 182.50 1106.06
52 Week High 223.00 | 52 Week Low 5.08
 
MX Mexico Most Active Stocks
AMXL 19.28 -0.36%
WALMEX 61.63 -0.21%
CEMEXCPO 17.61 -0.68%
FR 598.25 -40.29%
PV 7.92 %
GMEXICOB 152.49 2.41%
ALFAA 14.62 0.76%
GFNORTEO 171.21 -1.06%
NEMAKA 3.64 -1.36%
GENTERA 44.43 -1.38%
 
MX Mexico Top Gainers Stocks
ALEATIC 49.86 141.69%
MKSN 54.86 92.49%
GNW 160.21 57.38%
GNW 160.21 57.38%
HBCN 1200.00 28.34%
FIBRAUP18 39.19 20.58%
CLF 295.02 20.42%
CLF 295.02 20.42%
CLF 295.02 20.42%
CLF 295.02 20.42%
 
MX Mexico Top Losers Stocks
FR 598.25 -40.29%
FR 598.25 -40.29%
FR 598.25 -40.29%
FR 598.25 -40.29%
AGLN 502.53 -25.55%
IP 872.75 -23.50%
IP 872.75 -23.50%
IP 872.75 -23.50%
IP 872.75 -23.50%
IP 872.75 -23.50%
 
 
FGEN
Daily Charts
FGEN
Intraday Charts
Whats New @
Bazaartrend
FGEN
Free Analysis
 
FGEN Important Levels Intraday
RESISTANCE199.00
RESISTANCE199.00
RESISTANCE199.00
RESISTANCE199.00
RESISTANCE199.00
RESISTANCE199.00
RESISTANCE199.00
RESISTANCE199.00
 
FGEN Forecast October 2025
4th UP Forecast199
3rd UP Forecast199
2nd UP Forecast199
1st UP Forecast199
1st DOWN Forecast199
2nd DOWN Forecast199
3rd DOWN Forecast199
4th DOWN Forecast199
 
FGEN Weekly Forecast
4th UP Forecast201.89
3rd UP Forecast200.96
2nd UP Forecast200.39
1st UP Forecast199.82
1st DOWN Forecast198.18
2nd DOWN Forecast197.61
3rd DOWN Forecast197.04
4th DOWN Forecast196.11
 
FGEN Forecast2025
4th UP Forecast622.94
3rd UP Forecast486.98
2nd UP Forecast402.94
1st UP Forecast318.9
1st DOWN Forecast79.1
2nd DOWN Forecast-4.94
3rd DOWN Forecast-88.98
4th DOWN Forecast-224.94
 
 
FGEN Other Details
Segment EQ
Market Capital 21147756544.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
FGEN Address
FGEN
 
FGEN Latest News
 
Your Comments and Response on FibroGen Inc
 
FGEN Business Profile
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Address: 409 Illinois Street, San Francisco, CA, United States, 94158
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service